The EPO published patent application EP3898698A1, a new patent covering a Chimeric Antigen Receptor (CAR) targeting MUC18 for use in cancer therapy. The application was filed by Multitude Therapeutics Co., Ltd. with five named inventors. IPC classifications span A61K (medicinal preparations), C07K (peptides), and specifically cover CAR constructs, antibodies, and related therapeutic proteins.

Patent publications do not create immediate compliance obligations for third parties. Pharmaceutical and biotechnology companies developing CAR-T or antibody-based cancer therapies should note this publication for freedom-to-operate analysis. Companies with competing MUC18-targeting programs may need to evaluate potential overlap. No immediate action is required unless conducting IP due diligence.